Perioperative IMFINZI® (durvalumab) plus neoadjuvant enfortumab vedotin granted Priority Review in the US for patients with muscle-invasive bladder cancer

RegulatoryIMFINZIenfortumab vedotinPositive

AI Analysis

Summary

AstraZeneca's IMFINZI (durvalumab) in combination with neoadjuvant enfortumab vedotin has received Priority Review designation from the US FDA for perioperative treatment of patients with muscle-invasive bladder cancer.

Outcome Details

Priority Review granted for perioperative IMFINZI plus neoadjuvant enfortumab vedotin

Importance:7/10

Sentiment:

0.70

regulatorypriority_reviewoncologybladder_cancerimmunotherapycombination_therapy

Related Companies

$AZN

Read the original article

Published by yahoo_finance on September 25, 2026 11:00 AM

Read Original